DYNAMO Phase 2 trial

November 1, 2019November 11, 2019

Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show

News

Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 data ... Read more

April 12, 2018June 22, 2018

FDA Grants Priority Review to Duvelisib for Two Lymphoma Types

News

The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib’s full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for ... Read more

June 20, 2017June 20, 2017

Duvelisib Safe, Effective in Refractory Non-Hodgkin’s Lymphoma Patients, DYNAMO Study Shows

News

Treatment with Verastem’s duvelisib has shown sustained efficacy and safety in a trial with indolent non-Hodgkin’s lymphoma (iNHL) patients who had not responded well to Rituxan (rituximab) and chemotherapy or ... Read more

May 9, 2017

Verastem to Present Long-term Findings on Duvelisib’s Ability to Counter Non-Hodgkin’s Lymphoma

News

Verastem will present long-term findings on duvelisib’s ability to combat non-Hodgkin’s lymphoma at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 14-17. Forty-six of 129 lymphoma patients in the DYNAMO Phase 2 clinical ... Read more